Who was studied?
Two adults at a Florida clinic, both previously exposed to IV BPC-157, received monitored infusions.
- Participants
- 2 adults
- Duration
- 3 days of observation
- Funding
- Private clinic; funding not stated in the abstract
What did the study find?
The report described no adverse symptoms or changes in the selected blood markers and vital signs during its brief observation period.
What should you keep in mind?
Two prior users and three days cannot establish general or long-term safety. This was not a tissue-healing trial and did not test subcutaneous use.
Why it matters
A preliminary tolerability observation is a starting point for further research, not a broad safety conclusion.
Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study
Published 2025 · PMID 40131143
Summary by Peptide Lit, checked against the original abstract on October 8, 2026. Read the complete paper for detailed methods and safety results. This page explains published research; it does not recommend a treatment or dose.